Literature DB >> 29404893

Pathogenesis of non-functioning pituitary adenomas.

Maria Chiara Zatelli1.   

Abstract

The pathogenesis of non functioning pituitary adenomas (NFPA) is a complex process involving several factors, from molecular to genetic and epigenetic modifications, where tumor suppressor genes, oncogenes, cell cycle derangements have been demonstrated to play an important role. MicroRNAs (miRNAs) have also been identified as possible players in NFPA tumorigenesis and pituitary stem cells have been investigated for their potential role in pituitary tumor initiation. However, a critical role for paracrine signalling has also been highlighted. This review focuses on the current knowledge on the involvement of these factors in NFPA pathogenesis.

Entities:  

Keywords:  Non functioning pituitary adenomas; Pathogenesis; Signalling pathway derangements

Mesh:

Substances:

Year:  2018        PMID: 29404893     DOI: 10.1007/s11102-018-0874-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  80 in total

1.  Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.

Authors:  Lucia Brilli; Riccardo Danielli; Cristina Ciuoli; Luana Calabrò; Anna Maria Di Giacomo; Alfonso Cerase; Patrizia Paffetti; Fausta Sestini; Brunetta Porcelli; Michele Maio; Furio Pacini
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

2.  Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors.

Authors:  Katherine A Michaelis; Aaron J Knox; Mei Xu; Katja Kiseljak-Vassiliades; Michael G Edwards; Mark Geraci; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Margaret E Wierman
Journal:  Endocrinology       Date:  2011-08-02       Impact factor: 4.736

3.  Quantitative analysis of growth-related factors in human pituitary adenomas. Lowered insulin-like growth factor-I and its receptor mRNA in growth hormone-producing adenomas.

Authors:  F Otsuka; T Tamiya; T Yamauchi; T Ogura; T Ohmoto; H Makino
Journal:  Regul Pept       Date:  1999-08-31

4.  Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types.

Authors:  S Corbetta; A Pizzocaro; M Peracchi; P Beck-Peccoz; G Faglia; A Spada
Journal:  Clin Endocrinol (Oxf)       Date:  1997-11       Impact factor: 3.478

5.  miR-15a and miR-16-1 down-regulation in pituitary adenomas.

Authors:  Arianna Bottoni; Daniela Piccin; Federico Tagliati; Andrea Luchin; Maria Chiara Zatelli; Ettore C degli Uberti
Journal:  J Cell Physiol       Date:  2005-07       Impact factor: 6.384

6.  Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas.

Authors:  Henriett Butz; István Likó; Sándor Czirják; Péter Igaz; Mohammed Munayem Khan; Vladimir Zivkovic; Katalin Bálint; Márta Korbonits; Károly Rácz; Attila Patócs
Journal:  J Clin Endocrinol Metab       Date:  2010-07-28       Impact factor: 5.958

Review 7.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

8.  Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

Authors:  Maria Chiara Zatelli; Daniela Piccin; Cristina Vignali; Federico Tagliati; Maria Rosaria Ambrosio; Marta Bondanelli; Vincenzo Cimino; Antonio Bianchi; Herbert A Schmid; Massimo Scanarini; Alfredo Pontecorvi; Laura De Marinis; Giulio Maira; Ettore C degli Uberti
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

9.  HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies.

Authors:  Maria Trovato; Maria Luisa Torre; Marta Ragonese; Angela Simone; Rosy Scarfì; Valeria Barresi; Giuseppe Giuffrè; Salvatore Benvenga; Flavio F Angileri; Giovanni Tuccari; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Salvatore Cannavò
Journal:  Endocrine       Date:  2013-04-11       Impact factor: 3.633

10.  Overexpression of the Notch3 receptor and its ligand Jagged1 in human clinically non-functioning pituitary adenomas.

Authors:  Runchun Lu; Hua Gao; Hongyun Wang; Lei Cao; Jiwei Bai; Yazhuo Zhang
Journal:  Oncol Lett       Date:  2013-01-07       Impact factor: 2.967

View more
  7 in total

Review 1.  Aggressive nonfunctioning pituitary neuroendocrine tumors.

Authors:  Sérgio Portovedo; Leonardo Vieira Neto; Christina Maeda Takiya; Leandro Miranda-Alves; Paula Soares; Denise Pires de Carvalho
Journal:  Brain Tumor Pathol       Date:  2022-06-20       Impact factor: 3.154

2.  A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma.

Authors:  Jing Guo; Zhuang Wang; Yazhou Miao; Yutao Shen; Mingxuan Li; Lei Gong; Hongyun Wang; Yue He; Hua Gao; Qian Liu; Chuzhong Li; Yazhuo Zhang
Journal:  Oncol Rep       Date:  2018-11-02       Impact factor: 3.906

3.  Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features.

Authors:  Mari C Vázquez-Borrego; Antonio C Fuentes-Fayos; Eva Venegas-Moreno; Esther Rivero-Cortés; Elena Dios; Paloma Moreno-Moreno; Ainara Madrazo-Atutxa; Pablo Remón; Juan Solivera; Luiz E Wildemberg; Leandro Kasuki; Judith M López-Fernández; Mônica R Gadelha; María A Gálvez-Moreno; Alfonso Soto-Moreno; Manuel D Gahete; Justo P Castaño; Raúl M Luque
Journal:  Cancers (Basel)       Date:  2019-09-26       Impact factor: 6.639

Review 4.  [Update on mechanisms of pituitary tumorigenesis.]

Authors:  Laura Anahi Cecenarro; Gabriela Deisi Moyano Crespo; Jorge Humberto Mukdsi
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2021-12-28

Review 5.  Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches.

Authors:  Changxi Han; Shaojian Lin; Xingyu Lu; Li Xue; Zhe Bao Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-02       Impact factor: 5.555

6.  A Retrospective Trail Investigating Temozolomide Neoadjuvant Chemotherapy Combined with Radiotherapy in Low-Grade Pituitary Tumors.

Authors:  Jie Cui; Jianbo Shen; Xiaohong Ru; Zhihua Tian; Zhibin Duan; Guiping Chen; Min Li
Journal:  J Oncol       Date:  2022-03-25       Impact factor: 4.375

Review 7.  Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells.

Authors:  Roberto Würth; Stefano Thellung; Alessandro Corsaro; Federica Barbieri; Tullio Florio
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-20       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.